Completed PHASE1 INTERVENTIONAL 1-arm NCT02437422

Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease

A Phase Ib, Open-Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients With End-Stage Renal Disease (ESRD)

Sponsor: Prolong Pharmaceuticals

Conditions Renal Insufficiency, Chronic

Interventions SANGUINATE

Updated 7 times since 2017 Last updated: May 22, 2018 Started: Jun 5, 2015 Primary completion: Nov 18, 2015 Completion: Nov 18, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Renal Insufficiency, Chronic and is currently completed. Prolong Pharmaceuticals leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Dec 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 2 earlier versions

Feb 2017 — Dec 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Prolong Pharmaceuticals

Data source: Prolong Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States